The pomegranate is a medicinal plant that has been shown to have pharmacological significance and is high in bioactive polyphenols. The anti-inflammatory and anticancer properties of Punica granatum fruit extract and extracted ellagic acid were assessed in this study. Solvent partitioning and silica gel column chromatography were used to isolate ellagic acid, which produced 0.42% (w/w) of the dried extract. UV, IR and ¹H and ¹³C NMR spectroscopy validated structural elucidation and revealed distinctive signals that matched ellagic acid levels seen in the literature. Nitric oxide (NO) inhibition and carrageenan-induced paw edema in rats were used to measure anti-inflammatory efficacy. At the fourth hour after carrageenan injection, the crude extract (200mg/kg) and ellagic acid (50mg/kg) significantly decreased the volume of paw edema by 63.4% and 78.9%, respectively, in comparison to the control (p < 0.05). The isolated compound's greater inhibitory effect was demonstrated by the crude extract's IC50 of 42.3µg/mL in the NO assay, compared to ellagic acid's 18.6µg/mL. The MTT assay was used to assess anticancer activity against HeLa and MCF-7 cell lines. In contrast to the crude extract, which had IC50 values of 61.7µg/mL and 68.4µg/mL, ellagic acid displayed dose-dependent cytotoxicity with IC50 values of 24.8µg/mL (MCF-7) and 29.5µg/mL (HeLa). Cell viability was dramatically reduced in a concentration-dependent manner (p < 0.05), with ellagic acid showing the highest effectiveness. The results show that ellagic acid, a significant bioactive component of Punica granatum, is in charge of its anti-inflammatory and anticancer properties, indicating its potential as a lead molecule for additional therapeutic development.